Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription 03.06.2024 1 AIDS 1 BMJ 2 Clin Infect Dis 1 J Infect 1 J Infect Dis 2 J Virol 2 JAMA 1 Lancet 1 Minerva Pediatr (Torino) 1 MMWR Morb Mortal Wkly Rep 3 N Engl J Med 1 Nat Immunol 1 PLoS Comput Biol 5 PLoS One 1 Science 19 Vaccine 2 Virology 2 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. 
   Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV: Erratum.
   AIDS. 2024;38:1279.
   PubMed        
   
   

   
   BMJ

2. DYER O
   Covid-19: South African disclosures reveal secretive world of nations' vaccine contracts.
   BMJ. 2024;385:q1172.
   PubMed        
   
   

   
   Clin Infect Dis

3. WOLFE DN, Arangies E, David GL, Armstrong B, et al
   Development of Next-Generation COVID-19 Vaccines: BARDA Supported Phase 2b Study Designs.
   Clin Infect Dis. 2024 May 28:ciae286. doi: 10.1093.
   PubMed         Abstract available
   
   
4. HILL JA, Martens MJ, Young JH, Bhavsar K, et al
   SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.
   Clin Infect Dis. 2024 May 27:ciae291. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect

5. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
   The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials.
   J Infect. 2024;89:106187.
   PubMed         Abstract available
   
   

   
   J Infect Dis

6. GODIN A, Connor RI, Degefu HN, Rosato PC, et al
   Nasal and pharyngeal mucosal immunity to poliovirus in children following routine immunization with inactivated polio vaccine (IPV) in the United States of America.
   J Infect Dis. 2024 May 29:jiae264. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

7. CARTER DM, Darby CA, Lefoley BC, Crevar CJ, et al
   Correction for Carter et al., "Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses".
   J Virol. 2024 May 31:e0181323. doi: 10.1128/jvi.01813.
   PubMed        
   
   
8. DOETS K, Pijlman GP
   Subgenomic flavivirus RNA as key target for live-attenuated vaccine development.
   J Virol. 2024 May 29:e0010023. doi: 10.1128/jvi.00100.
   PubMed         Abstract available
   
   

   
   JAMA

9. VOELKER R
   What Is Hepatitis D Infection?
   JAMA. 2024 Apr 18. doi: 10.1001/jama.2024.1317.
   PubMed        
   
   
10. DAWOOD FS, Payne AB, McMorrow ML
    Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus.
    JAMA. 2024 Apr 11. doi: 10.1001/jama.2024.5859.
    PubMed        
    
    

    
    Lancet

11. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    PubMed         Abstract available
    
    

    
    Minerva Pediatr (Torino)

12. DENINA M, Papalia A, Scolfaro C, Silvestro E, et al
    Osteitis of the radius after bacillus Calmette-Guerin vaccination in international adopted children.
    Minerva Pediatr (Torino). 2024 May 27. doi: 10.23736/S2724-5276.24.07609.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

13. HAUSE AM, Moro PL, Baggs J, Zhang B, et al
    Early Safety Findings Among Persons Aged >/=60 Years Who Received a Respiratory Syncytial Virus Vaccine - United States, May 3, 2023-April 14, 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:489-494.
    PubMed        
    
    

    
    N Engl J Med

14. LIN DY, Du Y, Xu Y, Paritala S, et al
    Durability of XBB.1.5 Vaccines against Omicron Subvariants.
    N Engl J Med. 2024 May 29. doi: 10.1056/NEJMc2402779.
    PubMed        
    
    
15. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
    Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
    N Engl J Med. 2024;390:1827-1829.
    PubMed        
    
    
16. RUBIN EJ, Baden LR, Marrazzo J, Monto A, et al
    Audio Interview: The Current State of Avian Influenza.
    N Engl J Med. 2024 May 20. doi: 10.1056/NEJMe2406223.
    PubMed        
    
    

    
    Nat Immunol

17. SCHIFFNER T, Phung I, Ray R, Irimia A, et al
    Vaccination induces broadly neutralizing antibody precursors to HIV gp41.
    Nat Immunol. 2024 May 30. doi: 10.1038/s41590-024-01833.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

18. HLADISH TJ, Pillai AN, Pearson CAB, Toh KB, et al
    Evaluating targeted COVID-19 vaccination strategies with agent-based modeling.
    PLoS Comput Biol. 2024;20:e1012128.
    PubMed         Abstract available
    
    

    
    PLoS One

19. LE T, Flores M, Omaleki V, Hassani A, et al
    Assessing the impact of institutional mistrust on parental endorsement for COVID-19 vaccination among school communities in San Diego County, California.
    PLoS One. 2024;19:e0295618.
    PubMed         Abstract available
    
    
20. MERAYA AM, Syed MH, Shabi AA, Madkhali HA, et al
    Assessment of community pharmacists' knowledge, attitudes and their willingness to provide vaccination services in Saudi Arabia.
    PLoS One. 2024;19:e0304287.
    PubMed         Abstract available
    
    
21. ARBEL Y, Arbel Y, Kerner A, Kerner M, et al
    Can COVID-19 herd immunity be achieved at a city level?
    PLoS One. 2024;19:e0299574.
    PubMed         Abstract available
    
    
22. HUSSEIN K, Kokwaro G, Wafula F, Kassie GM, et al
    Assessing the influence of the health system on access to cervical cancer prevention, screening, and treatment services at public health centers in Addis Ababa, Ethiopia.
    PLoS One. 2024;19:e0300152.
    PubMed         Abstract available
    
    
23. TAMIR TT, Workneh BS, Mekonen EG, Zegeye AF, et al
    Coverage, spatial distribution and determinants of childhood inactivated poliovirus vaccine immunization in Ethiopia.
    PLoS One. 2024;19:e0301933.
    PubMed         Abstract available
    
    

    
    Science

24. ALLEN J, Watts DJ, Rand DG
    Quantifying the impact of misinformation and vaccine-skeptical content on Facebook.
    Science. 2024;384:eadk3451.
    PubMed         Abstract available
    
    

    
    Vaccine

25. MANSFIELD LN, Kahn BZ, Kokitkar S, Kritikos KI, et al
    HPV vaccine standing orders and communication in primary care: A qualitative study.
    Vaccine. 2024 May 29:S0264-410X(24)00554-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
26. NAKASE T, Brownwright T, Okunromade O, Egwuenu A, et al
    The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria.
    Vaccine. 2024 May 28:S0264-410X(24)00589-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
27. LUO H, Ma Y, Bi J, Li Z, et al
    Experimental and molecular dynamics simulation studies on the physical properties of three HBc-VLP derivatives as nanoparticle protein vaccine candidates.
    Vaccine. 2024 May 28:S0264-410X(24)00599-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
28. BATOOL R, Yousafzai MT, Mir F, Muhammad S, et al
    Longevity of serologic responses following a single dose of typhoid conjugate vaccine among children living with HIV in Pakistan: A prospective cohort study.
    Vaccine. 2024 May 28:S0264-410X(24)00625-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
29. BEGUM T, Efstathiou N, Bailey C, Guo P, et al
    Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review.
    Vaccine. 2024 May 27:S0264-410X(24)00600-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
30. EOM J, Kim Y, Kim D, Lee E, et al
    Cost-benefit analysis of human adenovirus vaccine development in a Korean military setting.
    Vaccine. 2024 May 27:S0264-410X(24)00622-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
31. MIRANDA-LOPEZ A, Gonzalez-Ortega O, Govea-Alonso DO, Betancourt-Mendiola L, et al
    Rational design and production of a chimeric antigen targeting Zika virus that induces neutralizing antibodies in mice.
    Vaccine. 2024 May 14:S0264-410X(24)00518-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
32. CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al
    Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
    Vaccine. 2024;42:3536-3546.
    PubMed         Abstract available
    
    
33. MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al
    Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.
    Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
34. BAK J, Hasan Q, Kissa J, Mere MO, et al
    Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23: How do we switch to a life course approach?
    Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
35. WU JY, Zhang W, Pu J, Liu Y, et al
    A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity.
    Vaccine. 2024 May 24:S0264-410X(24)00559-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
36. LYNETTE EJEZIE C, Cuccaro P, Savas LS, Shegog R, et al
    Regional differences in provider recommendation of HPV vaccines among 13-to-17 year old adolescents from 2019 to 2021.
    Vaccine. 2024 May 24:S0264-410X(24)00581-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
37. OKOLI GN, Neilson CJ, Grossman Moon A, Kimmel Supron H, et al
    Exploration of individual socioeconomic and health-related characteristics associated with human papillomavirus vaccination initiation and vaccination series completion among adult females: A comprehensive systematic evidence review with meta-analysis
    Vaccine. 2024 May 24:S0264-410X(24)00601-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
38. DOHERTY K, Bonnett L, Agbla SC, Beveridge NER, et al
    The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study.
    Vaccine. 2024 May 24:S0264-410X(24)00618-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
39. TREHARNE A, Patel Murthy B, Zell ER, Jones-Jack N, et al
    Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions.
    Vaccine. 2024 May 25:S0264-410X(24)00603-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
40. RENDUCHINTALA K, Arevalo M, Fonseca G, Haver MK, et al
    Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review.
    Vaccine. 2024 May 27:S0264-410X(24)00602-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
41. VASHIST K, Yankey D, Elam-Evans LD, Mu Y, et al
    Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years, National Immunization Surveys, 2019-2022.
    Vaccine. 2024 May 27:S0264-410X(24)00596-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
42. LUSTIG Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al
    Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Vaccine. 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
43. MENA-BUENO S, Garrido V, Romero F, Zabalza-Barangua A, et al
    Rev1Deltawzm vaccine candidate is safe in young and adult sheep and protects against Brucella ovis infection in rams.
    Vaccine. 2024 May 27:S0264-410X(24)00605-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

    
    Virology

44. TIAN Y, Deng Z, Chuai Z, Li C, et al
    A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge.
    Virology. 2024;596:110125.
    PubMed         Abstract available
    
    
45. YANG D, Wang X, Yang X, Qi S, et al
    Construction and immune effect evaluation of the S protein heptad repeat-based nanoparticle vaccine against porcine epidemic diarrhea virus.
    Virology. 2024;596:110113.
    PubMed         Abstract available
    
    

    
    Virus Res

46. LIN X, Yang F, Yan S, Wu H, et al
    Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus.
    Virus Res. 2024;345:199402.
    PubMed         Abstract available
    
    
47. ZHANG G, Peng Q, Liu S, Fan B, et al
    The glycosylation sites in RBD of spike protein attenuate the immunogenicity of PEDV AH2012/12.
    Virus Res. 2024;345:199381.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.